Morpholino

MO1-ptgs2a

ID
ZDB-MRPHLNO-050722-5
Name
MO1-ptgs2a
Previous Names
  • MO1-ptgs2
  • zCOX-2-A (1)
Target
Sequence
5' - AACCAGTTTATTCATTCCAGAAGTG - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
designed against translation start
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-ptgs2a
Phenotype
Phenotype resulting from MO1-ptgs2a
Phenotype of all Fish created by or utilizing MO1-ptgs2a
Phenotype Fish Conditions Figures
pronephric duct jag2b expression decreased distribution, abnormal TU + MO1-ptgs2a control Fig. 2 from Marra et al., 2019
pronephric duct pax2a expression decreased distribution, abnormal TU + MO1-ptgs2a control Fig. 2 from Marra et al., 2019
pronephric duct multi-ciliated epithelial cell has fewer parts of type multi-ciliated epithelial cell cilium, abnormal TU + MO1-ptgs2a control Fig. 4 from Marra et al., 2019
pronephric duct odf3b expression decreased distribution, abnormal TU + MO1-ptgs2a control Fig. 1 with image from Marra et al., 2019
brain hydrocephalic, abnormal TU + MO1-ptgs2a control Fig. S3 from Marra et al., 2019
pronephric proximal convoluted tubule multi-ciliated epithelial cell decreased amount, abnormal TU + MO1-ptgs2a control Fig. 3 from Marra et al., 2019
pericardium edematous, abnormal TU + MO1-ptgs2a control Fig. S3 from Marra et al., 2019
pronephric proximal straight tubule multi-ciliated epithelial cell odf3b expression decreased distribution, abnormal TU + MO1-ptgs2a control Fig. 3 from Marra et al., 2019
pronephric duct multi-ciliated epithelial cell decreased amount, abnormal TU + MO1-ptgs2a control Fig. 1 with imageFig. 2 from Marra et al., 2019
pronephric duct odf3b expression decreased distribution, abnormal TU + MO1-ptgs2a chemical treatment by environment: prostaglandin E2 Fig. 1 with image from Marra et al., 2019
pronephric duct multi-ciliated epithelial cell decreased amount, ameliorated TU + MO1-ptgs2a chemical treatment by environment: prostaglandin E2 Fig. 1 with image from Marra et al., 2019
exocrine pancreas prss1 expression amount, ameliorated WT + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 2 with image from Nissim et al., 2014
hematopoietic stem cell decreased amount, abnormal WT + MO1-ptgs2a + MO2-ptgs2a standard conditions Fig. S1 from North et al., 2007
exocrine pancreas prss1 expression decreased distribution, abnormal WT + MO1-ptgs2a + MO2-ptgs2a control Fig. 2 with image from Nissim et al., 2014
exocrine pancreas size, ameliorated WT + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 2 with image from Nissim et al., 2014
exocrine pancreas decreased size, abnormal WT + MO1-ptgs2a + MO2-ptgs2a control Fig. 2 with image from Nissim et al., 2014
liver decreased size, abnormal as3Tg + MO1-ptgs2a + MO2-ptgs2a control Fig. 1 with image from Nissim et al., 2014
liver EGFP expression decreased distribution, abnormal as3Tg + MO1-ptgs2a + MO2-ptgs2a control Fig. 1 with image from Nissim et al., 2014
liver size, ameliorated as3Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 1 with image from Nissim et al., 2014
liver EGFP expression amount, ameliorated as3Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 1 with image from Nissim et al., 2014
exocrine pancreas decreased size, abnormal zf578Tg + MO1-ptgs2a + MO2-ptgs2a control Fig. 2 with image from Nissim et al., 2014
exocrine pancreas size, ameliorated zf578Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Fig. 2 with image from Nissim et al., 2014
pronephric duct jag2b expression decreased distribution, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. 2 from Marra et al., 2019
pronephric duct pax2a expression decreased distribution, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. 2 from Marra et al., 2019
pronephric duct multi-ciliated epithelial cell has fewer parts of type multi-ciliated epithelial cell cilium, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. 4 from Marra et al., 2019
pronephric duct odf3b expression decreased distribution, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. 1 with image from Marra et al., 2019
brain hydrocephalic, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. S3 from Marra et al., 2019
pericardium edematous, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. S3 from Marra et al., 2019
pronephric duct multi-ciliated epithelial cell decreased amount, exacerbated TU + MO1-ptgs1 + MO1-ptgs2a control Fig. 2 from Marra et al., 2019
pronephric proximal convoluted tubule multi-ciliated epithelial cell decreased amount, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. 3 from Marra et al., 2019
pronephric proximal straight tubule multi-ciliated epithelial cell odf3b expression decreased distribution, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. 3 from Marra et al., 2019
pronephric duct multi-ciliated epithelial cell decreased amount, abnormal TU + MO1-ptgs1 + MO1-ptgs2a control Fig. 1 with image from Marra et al., 2019
pronephric duct odf3b expression decreased distribution, abnormal TU + MO1-ptgs1 + MO1-ptgs2a chemical treatment by environment: prostaglandin E2 Fig. 1 with image from Marra et al., 2019
pronephric duct multi-ciliated epithelial cell decreased amount, ameliorated TU + MO1-ptgs1 + MO1-ptgs2a chemical treatment by environment: prostaglandin E2 Fig. 1 with image from Marra et al., 2019
exocrine pancreas size, ameliorated zf578Tg + MO1-ptger2a + MO1-ptgs2a chemical treatment: prostaglandin E2 Fig. 2 with image from Nissim et al., 2014
exocrine pancreas decreased size, abnormal zf578Tg + MO1-ptger2a + MO1-ptgs2a control Fig. 2 with image from Nissim et al., 2014
Citations